Phan Kevin, Xu Joshua, Reddy Rajesh, Kalakoti Piyush, Nanda Anil, Fairhall Jacob
NeuroSpine Surgery Research Group, Prince of Wales Private Hospital, Sydney, Australia; Faculty of Medicine, University of Sydney, Sydney, Australia; Faculty of Medicine, University of New South Wales, Sydney, Australia.
Faculty of Medicine, University of Sydney, Sydney, Australia.
World Neurosurg. 2017 Jan;97:398-406. doi: 10.1016/j.wneu.2016.10.029. Epub 2016 Oct 15.
The pituitary adenoma causing acromegaly is typically resected through a transsphenoidal approach and visualized with an operating microscope or endoscope. We undertook a systematic review and meta-analysis examining the clinical efficacy of endoscopic and microsurgical approaches.
Relevant studies using either endoscopic or microscopic transsphenoidal approaches for growth hormone pituitary adenomas were identified until February 2016. Data were extracted and analyzed according to predefined clinical end points.
We identified 31 studies, in which 950 patients underwent endoscopic transsphenoidal resection and 2137 patients underwent microsurgical transsphenoidal resection. Patients undergoing microsurgery were less likely to present with hypothyroidism (10.7% vs. 19.1%, P = 0.033, 462 vs. 156 patients) and less likely to have macroadenomas (66.9% vs. 83.8%, P ≤ 0.001, 1484 vs. 884 patients); adenomas with cavernous sinus invasion (21.3% vs. 44.4%, P = 0.036, 592 vs. 558 patients); and a lower mean tumor volume (17.84 vs. 20.54 mm, P = 0.012, 158 vs. 248 patients). Patients treated via the endoscopic approach were more likely to achieve remission for noninvasive macroadenomas (83.8% vs. 66.9%, P ≤ 0.001, 115 vs. 365 patients). Sinusitis (15.6% vs. 2.6%, P < 0.001, 241 vs. 295 patients) and intraoperative cerebrospinal fluid leak (21.6% vs. 1.0%, P = 0.022, 697 vs. 127 patients) were more common in patients treated endoscopically, and meningitis (0.7% vs. 1.7%, P = 0.027, 511 vs. 1513 patients) was more common in patients undergoing a microsurgical approach.
Our study shows the clinical utility of the endoscopic approach and demonstrates potential benefits including increased remission rates with noninvasive macroadenomas and a lower rate of meningitis.
导致肢端肥大症的垂体腺瘤通常通过经蝶窦入路切除,并使用手术显微镜或内镜进行可视化操作。我们进行了一项系统评价和荟萃分析,以研究内镜和显微手术方法的临床疗效。
检索截至2016年2月使用内镜或显微经蝶窦入路治疗生长激素垂体腺瘤的相关研究。根据预定义的临床终点提取和分析数据。
我们纳入了31项研究,其中950例患者接受了内镜经蝶窦切除术,2137例患者接受了显微经蝶窦切除术。接受显微手术的患者发生甲状腺功能减退的可能性较小(10.7% 对19.1%,P = 0.033,462例对156例患者),患大腺瘤的可能性较小(66.9% 对83.8%,P≤0.001,1484例对884例患者);侵袭海绵窦的腺瘤(21.3% 对44.4%,P = 0.036,592例对558例患者);平均肿瘤体积较低(17.84对20.54mm,P = 0.012,158例对248例患者)。经内镜治疗的患者非侵袭性大腺瘤达到缓解的可能性更大(83.8% 对66.9%,P≤0.001,115例对365例患者)。鼻窦炎(15.6% 对2.6%,P < 0.001,241例对295例患者)和术中脑脊液漏(21.6% 对1.0%,P = 0.022,697例对127例患者)在内镜治疗的患者中更常见,而脑膜炎(0.7% 对1.7%,P = 0.027,511例对1513例患者)在接受显微手术的患者中更常见。
我们的研究显示了内镜入路的临床实用性,并证明了其潜在益处,包括非侵袭性大腺瘤缓解率增加和脑膜炎发生率较低。